Jazz Pharmaceuticals plc - Company Profile (NASDAQ:JAZZ)

About Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)

Jazz Pharmaceuticals plc - logoJazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).

Industry, Sector and Symbol:
  • Sector:
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:JAZZ
  • CUSIP: G5087110
  • Web: www.jazzpharma.com
Capitalization:
  • Market Cap: $9.07 billion
  • Outstanding Shares: 60,028,000
Average Prices:
  • 50 Day Moving Avg: $154.35
  • 200 Day Moving Avg: $130.66
  • 52 Week Range: $95.80 - $163.75
P/E:
  • Trailing P/E Ratio: 22.83
  • Foreward P/E Ratio: 11.50
  • P/E Growth: 0.77
Sales & Book Value:
  • Annual Revenue: $1.53 billion
  • Price / Sales: 5.93
  • Book Value: $33.05 per share
  • Price / Book: 4.57
Profitability:
  • EBIDTA: $760.64 million
  • Net Margins: 24.81%
  • Return on Equity: 30.50%
  • Return on Assets: 13.21%
Debt:
  • Debt-to-Equity Ratio: 1.25%
  • Current Ratio: 3.20%
  • Quick Ratio: 3.06%
Misc:
  • Average Volume: 527,648 shs.
  • Beta: 1.22
  • Short Ratio: 1.84
 

Frequently Asked Questions for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)

What is Jazz Pharmaceuticals plc -'s stock symbol?

Jazz Pharmaceuticals plc - trades on the NASDAQ under the ticker symbol "JAZZ."

How were Jazz Pharmaceuticals plc -'s earnings last quarter?

Jazz Pharmaceuticals plc - (NASDAQ:JAZZ) issued its quarterly earnings data on Tuesday, May, 9th. The company reported $1.41 EPS for the quarter, missing analysts' consensus estimates of $1.42 by $0.01. The company had revenue of $376.10 million for the quarter, compared to the consensus estimate of $376.58 million. Jazz Pharmaceuticals plc - had a return on equity of 30.50% and a net margin of 24.81%. The firm's revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the company earned $2.26 EPS. View Jazz Pharmaceuticals plc -'s Earnings History.

What guidance has Jazz Pharmaceuticals plc - issued on next quarter's earnings?

Jazz Pharmaceuticals plc - issued an update on its FY17 earnings guidance on Tuesday, May, 9th. The company provided EPS guidance of $10.70-11.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $11.13. The company issued revenue guidance of $1.625-1.700, compared to the consensus revenue estimate of $1.67 billion.

Where is Jazz Pharmaceuticals plc -'s stock going? Where will Jazz Pharmaceuticals plc -'s stock price be in 2017?

17 equities research analysts have issued 12 month price targets for Jazz Pharmaceuticals plc -'s shares. Their forecasts range from $150.00 to $210.00. On average, they anticipate Jazz Pharmaceuticals plc -'s stock price to reach $184.75 in the next twelve months. View Analyst Ratings for Jazz Pharmaceuticals plc -.

What are analysts saying about Jazz Pharmaceuticals plc - stock?

Here are some recent quotes from research analysts about Jazz Pharmaceuticals plc - stock:

  • 1. According to Zacks Investment Research, "Jazz’s missed estimates for earnings and sales in the first quarter of 2017. The company’s sleep disorder drug, Xyrem, is the only FDA-approved product for both cataplexy and EDS. However, Xyrem is facing patent challenges. Jazz has also been facing challenges in building sufficient inventory levels for leukemia drug Erwinaze due to constrained manufacturing capacity and may experience further supply disruptions this year. However, its lead pipeline candidate, JZP-110, being developed for the treatment of EDS in patients suffering from narcolepsy and OSA, complements its existing sleep disorder portfolio. In Oct 2016, Jazz commenced a rolling submission for its second pipeline candidate, Vyxeos, which was completed in early Apr 2017. Jazz’ shares outperformed the industry so far this year." (5/15/2017)
  • 2. Cantor Fitzgerald analysts commented, "TONES 2 hits on one primary endpoint, misses on another. On April 26, JAZZ disclosed results from the TONES 2 Phase 3 trial of JZP-110 in subjects with narcolepsy and who exhibit excessive daytime sleepiness (EDS). According to the company, although there was a statistically significant improvement in the Maintenance of Wakefulness Test (MWT), the improvement in in the Epworth Sleepiness Scale (ESS) was not statistically significant. JAZZ anticipates disclosing additional detail at the Associated Professional Sleep Societies’ (APSS) Sleep" meeting June 3-7 in (Boston). JZP-110 effectiveness in larger OSA market already demonstrated. On March 20, JAZZ announced that the co-primary endpoints (MWT and ESS) for the TONES 3 and 4 Phase 3 trials of JZP-110 in subjects with excessive sleepiness associated with obstructive sleep apnea (OSA) were met. NDA filing for both indications anticipated by YE17. Notwithstanding the somewhat mixed bag of data in EDS, JAZZ expects to file an NDA for OSA and EDS before the end of 2017." (4/27/2017)
  • 3. Mizuho analysts commented, "We raise our PT to $162 from $152 while reiterating our Buy rating following positive Phase III data in a key pipeline drug (JZP-110) in obstructive sleep apnea. Our PT went up due to increased likelihood of FDA approval." (3/21/2017)
  • 4. Cowen and Company analysts commented, "complete re-rating."Cacciatore comments, "We continue to believe Jazz is nearing a very interesting inflection point, as a favorable resolution to the Xyrem litigation is likely, which could extend the franchise to 2024/2025. Combined with JZP-110's potential $750MM+ opportunity to complement growing Defitelio, Erwinaze, and ultimately Vyxeos, we believe a complete re-rating is nearing. We would add here." (3/20/2017)
  • 5. BMO Capital Markets analysts commented, "JAZZ delivered on an important milestone with positive Phase 3 data for JZP-110 in two OSA studies that appear to demonstrate a very solid clinical profile for this novel wake-promoting agent. There had been some concerns into these data (first OSA studies for JZP-110), and we think this outcome significantly de-risks the program; Phase 3 data in narcolepsy set for 2Q17 and filing in late 2017. We reiterate our Outperform; JAZZ remains a top pick." (3/20/2017)

Are investors shorting Jazz Pharmaceuticals plc -?

Jazz Pharmaceuticals plc - saw a decline in short interest during the month of April. As of April 13th, there was short interest totalling 1,317,273 shares, a decline of 5.4% from the March 31st total of 1,392,707 shares. Based on an average daily volume of 751,756 shares, the days-to-cover ratio is presently 1.8 days.

Who are some of Jazz Pharmaceuticals plc -'s key competitors?

Who owns Jazz Pharmaceuticals plc - stock?

Jazz Pharmaceuticals plc -'s stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (12.46%), Vanguard Group Inc. (7.57%), BlackRock Inc. (5.38%), Janus Capital Management LLC (2.46%), Bank of New York Mellon Corp (2.42%) and Westfield Capital Management Co. LP (2.31%). Company insiders that own Jazz Pharmaceuticals plc - stock include Bruce C Cozadd, Heather Ann Mcsharry, Karen J Wilson, Karen L Smith, Kenneth W O'keefe, Michael Patrick Miller, Patrick G Enright, Paul Treacy, Rick E Winningham, Russell J Cox, Seamus Mulligan and Suzanne Sawochka Hooper. View Institutional Ownership Trends for Jazz Pharmaceuticals plc -.

Who sold Jazz Pharmaceuticals plc - stock? Who is selling Jazz Pharmaceuticals plc - stock?

Jazz Pharmaceuticals plc -'s stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Renaissance Technologies LLC, AQR Capital Management LLC, Pioneer Investment Management Inc., Ameriprise Financial Inc., Gotham Asset Management LLC, State Street Corp and Neuberger Berman Group LLC. Company insiders that have sold Jazz Pharmaceuticals plc - stock in the last year include Bruce C Cozadd, Karen J Wilson, Michael Patrick Miller, Patrick G Enright, Paul Treacy, Rick E Winningham, Russell J Cox, Seamus Mulligan and Suzanne Sawochka Hooper. View Insider Buying and Selling for Jazz Pharmaceuticals plc -.

Who bought Jazz Pharmaceuticals plc - stock? Who is buying Jazz Pharmaceuticals plc - stock?

Jazz Pharmaceuticals plc -'s stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Janus Capital Management LLC, TIAA CREF Investment Management LLC, American Century Companies Inc., KBC Group NV, Teachers Advisors LLC, Vanguard Group Inc. and Point72 Asset Management L.P.. Company insiders that have bought Jazz Pharmaceuticals plc - stock in the last two years include Karen L Smith and Kenneth W O'keefe. View Insider Buying and Selling for Jazz Pharmaceuticals plc -.

How do I buy Jazz Pharmaceuticals plc - stock?

Shares of Jazz Pharmaceuticals plc - can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Jazz Pharmaceuticals plc -'s stock price today?

One share of Jazz Pharmaceuticals plc - stock can currently be purchased for approximately $151.11.


MarketBeat Community Rating for Jazz Pharmaceuticals plc - (NASDAQ JAZZ)
Community Ranking:  3.9 out of 5 (  )
Outperform Votes:  609 (Vote Outperform)
Underperform Votes:  171 (Vote Underperform)
Total Votes:  780
MarketBeat's community ratings are surveys of what our community members think about Jazz Pharmaceuticals plc - and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ) (?)
Ratings Breakdown: 2 Hold Ratings, 15 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $184.75 (22.26% upside)

Analysts' Ratings History for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/22/2017Sanford C. BernsteinSet Price TargetMarket Perform$160.00 -> $176.00LowView Rating Details
5/15/2017Royal Bank of CanadaInitiated CoverageOutperform -> Outperform$210.00LowView Rating Details
5/10/2017Cowen and CompanyReiterated RatingOutperform$190.00LowView Rating Details
4/27/2017Leerink SwannSet Price TargetBuy$179.00LowView Rating Details
4/27/2017Cantor FitzgeraldReiterated RatingBuyHighView Rating Details
4/8/2017Piper Jaffray CompaniesSet Price TargetBuy$181.00LowView Rating Details
4/6/2017Deutsche Bank AGSet Price TargetBuy$176.00LowView Rating Details
4/6/2017Janney Montgomery ScottUpgradeNeutral -> Buy$138.00 -> $175.00HighView Rating Details
4/6/2017MizuhoDowngradeBuy -> Neutral$162.00 -> $150.00HighView Rating Details
3/20/2017BMO Capital MarketsReiterated RatingOutperform -> Positive$192.00HighView Rating Details
3/1/2017Stifel NicolausLower Price TargetBuy$200.00 -> $190.00N/AView Rating Details
2/22/2017Evercore ISIInitiated CoverageBuy$160.00N/AView Rating Details
2/16/2017GuggenheimReiterated RatingBuyN/AView Rating Details
1/19/2017SunTrust Banks, Inc.Reiterated RatingBuy$210.00N/AView Rating Details
1/18/2017Goldman Sachs Group IncReiterated RatingBuy$170.00N/AView Rating Details
1/18/2017Barclays PLCReiterated RatingOverweight$200.00N/AView Rating Details
6/18/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
4/5/2016Canaccord GenuityReiterated RatingBuy$170.00N/AView Rating Details
4/1/2016Northland SecuritiesReiterated RatingOutperform$175.00N/AView Rating Details
3/19/2016JPMorgan Chase & Co.Reiterated RatingBuyN/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)
Earnings by Quarter for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)
Earnings History by Quarter for Jazz Pharmaceuticals plc - (NASDAQ JAZZ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/20173/31/2017$1.42$1.41$376.58 million$376.10 millionViewListenView Earnings Details
2/28/2017Q416$2.65$1.91$398.91 million$396.62 millionViewListenView Earnings Details
11/8/2016Q316$2.61$2.16$389.34 million$374.00 millionViewListenView Earnings Details
8/9/2016Q216$2.80$2.63$376.40 million$381.00 millionViewN/AView Earnings Details
5/10/2016Q1$2.31$2.26$338.86 million$336.00 millionViewListenView Earnings Details
2/23/2016Q415$2.60$2.60$349.98 million$340.90 millionViewListenView Earnings Details
11/9/2015Q315$2.56$2.52$348.15 million$340.90 millionViewListenView Earnings Details
8/5/2015Q215$2.41$2.41$335.58 million$333.70 millionViewListenView Earnings Details
5/7/2015Q115$2.15$1.99$309.50 million$309.30 millionViewListenView Earnings Details
2/24/2015Q414$2.30$2.44$319.74 million$328.10 millionViewListenView Earnings Details
11/4/2014Q314$1.98$2.33$302.90 million$306.58 millionViewListenView Earnings Details
8/5/2014Q214$1.92$2.05$273.39 million$291.23 millionViewListenView Earnings Details
5/8/2014Q114$1.79$1.61$254.86 million$247.00 millionViewListenView Earnings Details
2/25/2014Q413$1.78$1.72$238.12 million$235.80 millionViewListenView Earnings Details
11/5/2013Q313$1.67$1.78$227.38 million$232.20 millionViewListenView Earnings Details
8/6/2013Q2 2013$1.52$1.43$208.71 million$208.30 millionViewListenView Earnings Details
5/7/2013Q1 2013$1.35$1.37$189.92 million$196.20 millionViewListenView Earnings Details
2/26/2013Q4 2012$1.41$1.53$183.80 million$183.70 millionViewListenView Earnings Details
11/8/2012Q312$1.31$1.29$178.57 million$175.50 millionViewN/AView Earnings Details
8/7/2012$1.05$1.09ViewN/AView Earnings Details
5/8/2012$0.90$0.91ViewN/AView Earnings Details
11/1/2011$0.89$0.94ViewN/AView Earnings Details
7/28/2011$0.67$0.82ViewN/AView Earnings Details
5/3/2011$0.57$0.59ViewN/AView Earnings Details
3/7/2011$0.60$0.63ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20172$1.89$2.84$2.37
Q3 20171$2.47$2.47$2.47
Q4 20171$2.78$2.78$2.78
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)
Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 88.56%
Insider Trades by Quarter for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)
Institutional Ownership by Quarter for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)
Insider Trades by Quarter for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/15/2017Michael Patrick MillerEVPSell200$152.98$30,596.00View SEC Filing  
5/11/2017Bruce C CozaddCEOSell30,000$153.47$4,604,100.00View SEC Filing  
5/9/2017Suzanne Sawochka HooperEVPSell2,500$160.00$400,000.00View SEC Filing  
4/27/2017Karen J WilsonSVPSell1,275$160.00$204,000.00View SEC Filing  
4/27/2017Suzanne Sawochka HooperEVPSell2,500$160.00$400,000.00View SEC Filing  
4/17/2017Michael Patrick MillerSVPSell200$152.56$30,512.00View SEC Filing  
4/11/2017Bruce C CozaddCEOSell1,000$152.12$152,120.00View SEC Filing  
4/10/2017Karen J WilsonSVPSell11,458$152.24$1,744,365.92View SEC Filing  
3/15/2017Michael Patrick MillerSVPSell200$137.89$27,578.00View SEC Filing  
3/6/2017Paul TreacySVPSell884$131.97$116,661.48View SEC Filing  
2/15/2017Michael Patrick MillerSVPSell200$134.55$26,910.00View SEC Filing  
1/18/2017Russell J. CoxCOOSell4,000$128.75$515,000.00View SEC Filing  
1/17/2017Michael Patrick MillerSVPSell200$115.93$23,186.00View SEC Filing  
12/15/2016Michael Patrick MillerSVPSell200$103.09$20,618.00View SEC Filing  
12/2/2016Patrick G EnrightDirectorSell677$101.80$68,918.60View SEC Filing  
11/15/2016Michael Patrick MillerSVPSell200$112.19$22,438.00View SEC Filing  
11/14/2016Kenneth W O'keefeDirectorBuy2,000$113.84$227,680.00View SEC Filing  
10/17/2016Michael Patrick MillerSVPSell200$118.16$23,632.00View SEC Filing  
9/19/2016Michael Patrick MillerSVPSell200$126.17$25,234.00View SEC Filing  
8/25/2016Seamus MulliganDirectorSell27,968$128.32$3,588,853.76View SEC Filing  
8/16/2016Paul TreacySVPSell1,292$137.47$177,611.24View SEC Filing  
8/15/2016Michael Patrick MillerSVPSell100$136.45$13,645.00View SEC Filing  
8/15/2016Rick E WinninghamDirectorSell633$136.45$86,372.85View SEC Filing  
8/12/2016Karen L SmithInsiderBuy608$137.10$83,356.80View SEC Filing  
8/9/2016Bruce C. CozaddCEOSell1,000$150.00$150,000.00View SEC Filing  
8/9/2016Russell J. CoxCOOSell4,000$148.66$594,640.00View SEC Filing  
7/15/2016Michael Patrick MillerSVPSell100$142.43$14,243.00View SEC Filing  
7/13/2016Karen L SmithCMOBuy580$143.63$83,305.40View SEC Filing  
6/15/2016Michael Patrick MillerSVPSell100$149.64$14,964.00View SEC Filing  
6/13/2016Karen L SmithCMOBuy557$149.61$83,332.77View SEC Filing  
5/16/2016Heather Ann McsharryDirectorSell697$145.20$101,204.40View SEC Filing  
5/16/2016Michael Patrick MillerSVPSell100$145.20$14,520.00View SEC Filing  
4/25/2016Karen J WilsonSVPSell604$160.00$96,640.00View SEC Filing  
4/15/2016Michael Patrick MillerSVPSell100$145.79$14,579.00View SEC Filing  
4/13/2016Karen J WilsonSVPSell5,007$150.00$751,050.00View SEC Filing  
4/12/2016Russell J CoxCOOSell4,000$136.98$547,920.00View SEC Filing  
4/7/2016Karen J WilsonSVPSell2,161$140.90$304,484.90View SEC Filing  
3/15/2016Michael Patrick MillerSVPSell100$129.17$12,917.00View SEC Filing  
3/8/2016Bruce C CozaddCEOSell2,500$126.04$315,100.00View SEC Filing  
2/29/2016Paul TreacySVPSell354$123.48$43,711.92View SEC Filing  
2/23/2016Seamus MulliganDirectorSell27,968$122.71$3,431,953.28View SEC Filing  
2/16/2016Michael Patrick MillerSVPSell100$115.63$11,563.00View SEC Filing  
2/10/2016Patrick G EnrightDirectorSell10,000$117.92$1,179,200.00View SEC Filing  
2/9/2016Bruce C CozaddCEOSell2,500$111.37$278,425.00View SEC Filing  
1/15/2016Michael Patrick MillerSVPSell100$122.66$12,266.00View SEC Filing  
1/12/2016Bruce C CozaddCEOSell2,500$123.81$309,525.00View SEC Filing  
1/5/2016Patrick G EnrightDirectorSell10,000$138.09$1,380,900.00View SEC Filing  
12/15/2015Michael Patrick MillerSVPSell100$136.99$13,699.00View SEC Filing  
12/8/2015Bruce C CozaddCEOSell2,500$139.72$349,300.00View SEC Filing  
12/2/2015Patrick G EnrightDirectorSell10,424$146.67$1,528,888.08View SEC Filing  
11/23/2015Seamus MulliganDirectorSell27,968$145.86$4,079,412.48View SEC Filing  
11/10/2015Bruce C CozaddCEOSell2,500$128.53$321,325.00View SEC Filing  
11/10/2015Patrick G EnrightDirectorSell10,000$135.29$1,352,900.00View SEC Filing  
10/21/2015Suzanne Sawochka HooperEVPSell2,000$125.00$250,000.00View SEC Filing  
10/13/2015Bruce C CozaddCEOSell2,500$131.50$328,750.00View SEC Filing  
10/5/2015Patrick G EnrightDirectorSell10,000$133.79$1,337,900.00View SEC Filing  
9/25/2015Michael Patrick MillerSVPSell100$145.23$14,523.00View SEC Filing  
9/8/2015Bruce C. CozaddCEOSell2,500$163.07$407,675.00View SEC Filing  
9/1/2015Patrick G EnrightDirectorSell10,000$165.99$1,659,900.00View SEC Filing  
7/14/2015Bruce C CozaddCEOSell5,000$177.79$888,950.00View SEC Filing  
7/14/2015Suzanne Sawochka HooperEVPSell4,000$177.79$711,160.00View SEC Filing  
7/6/2015Patrick G EnrightDirectorSell10,000$177.11$1,771,100.00View SEC Filing  
6/9/2015Bruce C CozaddCEOSell5,000$173.16$865,800.00View SEC Filing  
6/9/2015Suzanne Sawochka HooperEVPSell4,000$173.16$692,640.00View SEC Filing  
6/2/2015Karen J WilsonSVPSell5,751$179.59$1,032,822.09View SEC Filing  
6/1/2015Karen J WilsonSVPSell5,494$179.57$986,557.58View SEC Filing  
4/14/2015Bruce C CozaddCEOSell5,000$181.45$907,250.00View SEC Filing  
4/14/2015Suzanne Sawochka HooperEVPSell4,000$181.45$725,800.00View SEC Filing  
3/25/2015Seamus MulliganDirectorSell50,000$174.59$8,729,500.00View SEC Filing  
1/5/2015Patrick G EnrightDirectorSell10,000$160.25$1,602,500.00View SEC Filing  
12/26/2014Seamus MulliganDirectorSell50,000$163.40$8,170,000.00View SEC Filing  
12/12/2014Patrick G EnrightDirectorSell2,343$170.98$400,606.14View SEC Filing  
12/9/2014Bruce C CozaddCEOSell5,000$178.79$893,950.00View SEC Filing  
12/9/2014Suzanne Sawochka HooperEVPSell1,852$178.79$331,119.08View SEC Filing  
12/1/2014Patrick G EnrightDirectorSell10,000$172.74$1,727,400.00View SEC Filing  
11/24/2014Jeffrey K TobiasCMOSell4,598$170.12$782,211.76View SEC Filing  
11/7/2014Iain McgillSVPSell7,066$172.03$1,215,563.98View SEC Filing  
10/10/2014Jeffrey K TobiasCMOSell1,000$154.04$154,040.00View SEC Filing  
10/6/2014Patrick G EnrightDirectorSell10,000$160.56$1,605,600.00View SEC Filing  
9/25/2014Seamus MulliganDirectorSell50,000$163.16$8,158,000.00View SEC Filing  
9/24/2014Seamus MulliganDirectorSell35,294$163.70$5,777,627.80View SEC Filing  
9/12/2014Jeffrey K TobiasCMOSell1,000$171.22$171,220.00View SEC Filing  
9/11/2014Karen J WilsonSVPSell3,000$175.00$525,000.00View SEC Filing  
9/11/2014Seamus MulliganDirectorSell50,000$175.00$8,750,000.00View SEC Filing  
9/9/2014Bruce C CozaddCEOSell5,000$170.32$851,600.00View SEC Filing  
9/8/2014Karen J WilsonSVPSell2,500$170.00$425,000.00View SEC Filing  
9/8/2014Suzanne Sawochka HooperEVPSell1,852$168.00$311,136.00View SEC Filing  
8/12/2014Bruce C CozaddCEOSell5,000$133.15$665,750.00View SEC Filing  
8/12/2014Suzanne Sawochka HooperEVPSell1,185$133.15$157,782.75View SEC Filing  
8/11/2014Jeffrey K TobiasCMOSell4,933$135.42$668,026.86View SEC Filing  
7/8/2014Bruce C CozaddCEOSell5,000$155.00$775,000.00View SEC Filing  
7/8/2014Suzanne Sawochka HooperEVPSell1,853$155.00$287,215.00View SEC Filing  
7/7/2014Karen J WilsonSVPSell2,500$165.00$412,500.00View SEC Filing  
6/25/2014Seamus MulliganDirectorSell50,000$149.69$7,484,500.00View SEC Filing  
6/20/2014Russell J CoxCOOSell2,000$155.00$310,000.00View SEC Filing  
6/17/2014Fintan KeeganEVPSell3,750$150.00$562,500.00View SEC Filing  
6/10/2014Bruce C CozaddCEOSell5,000$142.34$711,700.00View SEC Filing  
5/16/2014Jeffrey TobiasCMOSell1,000$128.01$128,010.00View SEC Filing  
5/13/2014Bruce CozaddCEOSell5,000$128.92$644,600.00View SEC Filing  
4/17/2014Rick WinninghamDirectorSell27,500$140.00$3,850,000.00View SEC Filing  
4/14/2014Jeffrey TobiasCMOSell3,000$128.54$385,620.00View SEC Filing  
4/8/2014Bruce CozaddCEOSell5,000$123.18$615,900.00View SEC Filing  
3/10/2014Jeffrey TobiasCMOSell3,000$152.99$458,970.00View SEC Filing  
3/6/2014Fintan KeeganEVPSell4,640$159.90$741,936.00View SEC Filing  
3/4/2014Seamus MulliganDirectorSell550,000$156.25$85,937,500.00View SEC Filing  
3/3/2014Patrick EnrightDirectorSell559,628$152.39$85,281,710.92View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)
Latest Headlines for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)
Source:
DateHeadline
americanbankingnews.com logoJazz Pharmaceuticals plc - (JAZZ) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 29 at 9:06 PM
finance.yahoo.com logoJazz Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : JAZZ-US : May 29, 2017
finance.yahoo.com - May 29 at 9:24 AM
prnewswire.com logoJazz Pharmaceuticals Announces Webcast Discussion of Data to be Presented at APSS - PR Newswire (press release)
www.prnewswire.com - May 24 at 11:00 PM
finance.yahoo.com logoJazz Pharmaceuticals to Present Phase 3 Data on JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy and with Obstructive Sleep Apnea, During 31st Annual SLEEP Meeting
finance.yahoo.com - May 24 at 5:57 PM
finance.yahoo.com logoJazz Pharmaceuticals Announces Webcast Discussion of Data to be Presented at APSS
finance.yahoo.com - May 24 at 5:57 PM
finance.yahoo.com logoETFs with exposure to Jazz Pharmaceuticals Plc : May 22, 2017
finance.yahoo.com - May 22 at 5:29 PM
americanbankingnews.com logoJazz Pharmaceuticals plc - (JAZZ) Receives "Market Perform" Rating from Sanford C. Bernstein
www.americanbankingnews.com - May 22 at 12:44 PM
finance.yahoo.com logoJazz Pharmaceuticals Plc :JAZZ-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017
finance.yahoo.com - May 19 at 10:34 AM
finance.yahoo.com logoJazz Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : JAZZ-US : May 18, 2017
finance.yahoo.com - May 18 at 9:13 AM
nasdaq.com logoThe Implied Analyst 12-Month Target For PPH
www.nasdaq.com - May 17 at 9:51 AM
prnewswire.com logoJazz Pharmaceuticals Announces Participation in Two Upcoming ... - PR Newswire (press release)
www.prnewswire.com - May 16 at 10:55 PM
finance.yahoo.com logoJazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences
finance.yahoo.com - May 16 at 5:54 PM
americanbankingnews.com logoMichael Patrick Miller Sells 200 Shares of Jazz Pharmaceuticals plc - (JAZZ) Stock
www.americanbankingnews.com - May 15 at 8:21 PM
americanbankingnews.com logoJazz Pharmaceuticals plc - (JAZZ) Coverage Initiated by Analysts at Royal Bank of Canada
www.americanbankingnews.com - May 15 at 9:34 AM
americanbankingnews.com logoJazz Pharmaceuticals plc - (JAZZ) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - May 15 at 9:14 AM
americanbankingnews.com logoJazz Pharmaceuticals plc - (JAZZ) CEO Bruce C. Cozadd Sells 30,000 Shares
www.americanbankingnews.com - May 12 at 10:51 PM
finance.yahoo.com logo4 of the Cheapest Biotech Stocks in the World
finance.yahoo.com - May 11 at 3:27 PM
americanbankingnews.com logoJazz Pharmaceuticals plc - (JAZZ) Announces Earnings Results
www.americanbankingnews.com - May 11 at 12:27 AM
americanbankingnews.com logoInsider Selling: Jazz Pharmaceuticals plc - (JAZZ) EVP Sells 2,500 Shares of Stock
www.americanbankingnews.com - May 10 at 11:22 PM
finance.yahoo.com logoEdited Transcript of JAZZ earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 10 at 6:13 PM
americanbankingnews.com logoJazz Pharmaceuticals plc - (JAZZ) Earns Outperform Rating from Cowen and Company
www.americanbankingnews.com - May 10 at 4:02 PM
nasdaq.com logoJazz Pharmaceuticals (JAZZ) Misses Q1 Earnings & Sales - Nasdaq
www.nasdaq.com - May 10 at 1:10 PM
prnewswire.com logoJazz Pharmaceuticals Announces First Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - May 10 at 1:10 PM
seekingalpha.com logoJazz Pharmaceuticals Plc (JAZZ) Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 10 at 1:10 PM
finance.yahoo.com logoJazz Pharmaceuticals (JAZZ) Misses Q1 Earnings & Sales
finance.yahoo.com - May 10 at 1:10 PM
marketbeat.com logoJazz misses Street 1Q forecasts
marketbeat.com - May 9 at 6:26 PM
reuters.com logoBRIEF-Jazz pharmaceuticals announces Q1 2017 financial results
www.reuters.com - May 9 at 5:50 PM
finance.yahoo.com logoInvestor Network: Jazz Pharmaceuticals Plc to Host Earnings Call
finance.yahoo.com - May 9 at 5:50 PM
finance.yahoo.com logoJazz Pharmaceuticals Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 5:50 PM
finance.yahoo.com logoJazz Pharma Reports Lagging First-Quarter Sales, Profits
finance.yahoo.com - May 9 at 5:50 PM
americanbankingnews.com logoJazz Pharmaceuticals plc - (JAZZ) Updates FY17 Earnings Guidance
www.americanbankingnews.com - May 9 at 5:26 PM
finance.yahoo.com logoAllergan's Q1 Sales Expected To Slip As Jazz Pharma Outperforms
finance.yahoo.com - May 8 at 5:42 PM
americanbankingnews.com logoAnalysts Offer Predictions for Jazz Pharmaceuticals plc -'s Q2 2017 Earnings (JAZZ)
www.americanbankingnews.com - May 8 at 8:15 AM
americanbankingnews.com logoJazz Pharmaceuticals plc - (JAZZ) Receives Daily News Sentiment Score of 0.16
www.americanbankingnews.com - May 4 at 2:34 PM
americanbankingnews.com logoJazz Pharmaceuticals plc - (JAZZ) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 2 at 10:48 PM
americanbankingnews.com logoJazz Pharmaceuticals plc - (JAZZ) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - May 2 at 1:56 PM
americanbankingnews.com logoJazz Pharmaceuticals plc - (JAZZ) Getting Somewhat Positive Press Coverage, AlphaOne Reports
www.americanbankingnews.com - May 1 at 6:04 PM
americanbankingnews.com logoJazz Pharmaceuticals plc - (JAZZ) Short Interest Update
www.americanbankingnews.com - April 30 at 1:02 PM
americanbankingnews.com logoZacks: Analysts Anticipate Jazz Pharmaceuticals plc - (JAZZ) Will Post Quarterly Sales of $378.47 Million
www.americanbankingnews.com - April 29 at 10:19 AM
americanbankingnews.com logoSomewhat Favorable News Coverage Very Likely to Impact Jazz Pharmaceuticals plc - (JAZZ) Stock Price
www.americanbankingnews.com - April 28 at 11:06 PM
prnewswire.com logoJazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 2 Study of JZP-110 in Narcolepsy Patients ... - PR Newswire (press release)
www.prnewswire.com - April 28 at 9:54 AM
americanbankingnews.com logoJazz Pharmaceuticals plc - (JAZZ) SVP Sells $204,000.00 in Stock
www.americanbankingnews.com - April 28 at 12:00 AM
americanbankingnews.com logoLeerink Swann Analysts Give Jazz Pharmaceuticals plc - (JAZZ) a $179.00 Price Target
www.americanbankingnews.com - April 27 at 7:20 PM
americanbankingnews.com logo$1.32 EPS Expected for Jazz Pharmaceuticals plc - (JAZZ) This Quarter
www.americanbankingnews.com - April 27 at 8:50 AM
americanbankingnews.com logoJazz Pharmaceuticals plc -'s (JAZZ) "Buy" Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - April 27 at 8:22 AM
streetinsider.com logoJazz Pharma (JAZZ) Announces Positive Results from Phase 3 TONES 2 Study of JZP-110 for Narcolepsy
www.streetinsider.com - April 26 at 7:17 PM
finance.yahoo.com logoJazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 2 Study of JZP-110 in Narcolepsy Patients with Excessive Sleepiness
finance.yahoo.com - April 26 at 7:17 PM
finance.yahoo.com logoJazz Pharmaceuticals to Report 2017 First Quarter Financial Results on May 9, 2017
finance.yahoo.com - April 25 at 5:29 PM
americanbankingnews.com logoJazz Pharmaceuticals plc - (JAZZ) Receives News Sentiment Rating of 0.11
www.americanbankingnews.com - April 25 at 5:29 PM
nasdaq.com logoD-Day For CAPR Today, OMED Hands Out Pink Slips, JAZZ Hits Right Notes...
www.nasdaq.com - April 25 at 10:37 AM

Social

Chart

Jazz Pharmaceuticals plc - (JAZZ) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff